In the Phase III GIMEMA ALL2820 trial, presented at ASH, 94 percent of patients who received the chemo-free regimen had a ...

In the most recent data presented at the meeting, the CAR T-cell therapy demonstrated a 96 percent overall response rate.

In a large analysis presented at ASH's annual meeting, researchers reported that patients' MRD status after intensive chemo can predict their survival.

One study found frail patients tend to have worse survival outcomes on the therapy, but another challenged the idea that ...

The results mark a setback for the hypothesis that drugs like semaglutide could provide a neuroprotective effect for patients ...

The Phase III trial, testing the drug in patients whose cancers are Philadelphia chromosome-positive, will expand to the US and Europe.

AACR held an event on Capitol Hill with the NCI director and a legislator to discuss government efforts to support pediatric cancer research.

The firm is developing Lumevoq as a treatment for Leber hereditary optic neuropathy caused by mutations in the ND4 mitochondrial gene.

The agency approved the autologous CAR T-cell therapy based on data showing that around 62 percent of patients had no signs of cancer after a single infusion.

The regimen reduces the steps required to administer tumor-specific antibodies and a radioactive payload to carcinoembryonic antigen-positive tumors.

In the Phase I portion of the trial, there were no reported serious adverse events and a 100 percent complete response rate at the highest dose level of EB103.